DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Luciferase assay are 130

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_3627	Cyanovirin-N	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	15073681
DrugRepV_3628	Cyanovirin-N	NA	NA	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	15073681
DrugRepV_3629	Cyanovirin-N	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	15073681
DrugRepV_3630	N-methyl-5,7-dinitro-N-propylquinolin-8-amine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3631	2-[3-(4-chlorophenyl)-1-(3-methoxyphenyl)-3-oxopropyl]propanedinitrile	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3632	(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,9,15(20)-pentaene-14,18-dione	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3633	2-[(1E)-2-(5-nitrofuran-2-yl)ethenyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-one	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3634	N-(3,4-dichlorophenyl)-5-nitrofuran-2-carboxamide	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3635	7-[(furan-2-yl)methyl]-3-[3-(1H-imidazol-1-yl)propyl]-5,6-diphenyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-imine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3636	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3637	N,N-bis(4-methylphenyl)pyridin-3-amine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3638	N-methyl-5,7-dinitro-N-propylquinolin-8-amine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3639	2-[3-(4-chlorophenyl)-1-(3-methoxyphenyl)-3-oxopropyl]propanedinitrile	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3640	(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,9,15(20)-pentaene-14,18-dione	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3641	2-[(1E)-2-(5-nitrofuran-2-yl)ethenyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-one	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3642	N-(3,4-dichlorophenyl)-5-nitrofuran-2-carboxamide	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3643	7-[(furan-2-yl)methyl]-3-[3-(1H-imidazol-1-yl)propyl]-5,6-diphenyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-imine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3644	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3645	N,N-bis(4-methylphenyl)pyridin-3-amine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3646	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3647	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3648	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Rift Valley fever virus	MP12	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3649	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Influenza virus	California/07/2009		Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3650	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Influenza virus	Brisbane/10/2007		Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3651	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3652	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3653	2-methyl-4-phenyl-1H-naphtho[2,3-b][1,4]diazepine hydrochloride	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3654	2-(4-chlorophenyl)-7,8-dimethyl-4-(trifluoromethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3655	2-(1,1,2,2,2-pentafluoroethyl)-4-phenyl-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3656	7,8-dichloro-2-(1,1,2,2,2-pentafluoroethyl)-4-phenyl-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3657	2-[4-(trifluoromethyl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3658	2-(4-methylphenyl)-4-(trifluoromethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3659	4-methoxy-2-[4-(trifluoromethyl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3660	2-[4-(thiophen-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3661	4-chloro-2-[4-(furan-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3662	4-methoxy-2-[4-(thiophen-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3663	2-[4-(furan-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3664	2-[4-(3-nitrophenyl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3697	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	24713118
DrugRepV_3698	6-Azauridine	NA	Cancer	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	24713118
DrugRepV_3699	2-C-Methylcytidine	NA	Hepatitis C virus	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	Experimental	24713118
DrugRepV_3700	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	24713118
DrugRepV_3701	6-Azauridine	NA	Cancer	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	24713118
DrugRepV_3702	2-C-Methylcytidine	NA	Hepatitis C virus	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Experimental	24713118
DrugRepV_3993	Genistein	Antihelmintic	Prostate cancer	Lassa virus	NA	NA	Luciferase assay	Decrease (90 %)	Investigational	21947546
DrugRepV_3994	Genistein	Antihelmintic	Prostate cancer	Marburg virus	NA	NA	Luciferase assay	Decrease (75 %)	Investigational	21947546
DrugRepV_3995	Genistein	Antihelmintic	Prostate cancer	Ebola virus	NA	NA	Luciferase assay	Decrease (87 %)	Investigational	21947546
DrugRepV_3996	Tyrphostin AG1478	NA	NA	Lassa virus	NA	NA	Luciferase assay	Decrease (100 %)	NA	21947546
DrugRepV_3997	Tyrphostin AG1478	NA	NA	Marburg virus	NA	NA	Luciferase assay	Decrease (100 %)	NA	21947546
DrugRepV_3998	Tyrphostin AG1478	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (100 %)	NA	21947546
DrugRepV_3999	Genistein-Tyrphostin AG1478	NA	NA	Lassa virus	NA	NA	Luciferase assay	Decrease (99 %)	NA	21947546
DrugRepV_4000	Genistein-Tyrphostin AG1478	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (99 %)	NA	21947546
DrugRepV_4486	Brincidofovir	NA	Viral infections	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4487	CMX029	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4488	CMX021	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4489	CMX028	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4490	CMX16669	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4491	CMX16663	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4492	CMX167	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4493	CMX157	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4494	CMX101	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4495	CMX004	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4496	CMX16689	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4593	3-(benzyloxy)-7-[(3-chlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4594	3-[(2-chlorophenyl)methoxy]-7-[(3-chlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4595	3,7-bis[(3-chlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4596	7-[(3-chlorophenyl)methoxy]-3-[(2,4-dichlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4597	7-[(3-chlorophenyl)methoxy]-8-hydroxy-3-[(2-iodophenyl)methoxy]-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4598	7-[(3-chlorophenyl)methoxy]-8-hydroxy-3-[(3-iodophenyl)methoxy]-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4599	2-[({6-[(3-chlorophenyl)methoxy]-5-hydroxy-4-oxo-1,4-dihydronaphthalen-2-yl}oxy)methyl]benzonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4600	(2Z)-4-(3-{[(4-chlorophenyl)methyl]amino}phenyl)-2-hydroxy-4-oxobut-2-enoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4601	5,7-dihydroxy-3-[(3-nitrophenyl)methoxy]-2-phenyl-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4602	3-{[(3,5-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy]methyl}benzonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4683	NITD008	Antiviral	NA	Zika virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	29288699
DrugRepV_4822	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4823	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4824	Dalbavancin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4825	Oritavancin	Antiinfectives For Systemic Use	Acute bacterial skin | Skin structure infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4826	Telavancin	Antiinfectives For Systemic Use	Skin infections (Bacterial)	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4827	Vancomycin	Alimentary Tract and Metabolism; Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4828	CTSL inhibitor	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	26953343
DrugRepV_4829	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Middle East respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4830	Dalbavancin	Antiinfectives For Systemic Use	Bacterial infections	Middle East respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4831	Oritavancin	Antiinfectives For Systemic Use	Acute bacterial skin | Skin structure infections	Middle East respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4832	Telavancin	Antiinfectives For Systemic Use	Skin infections (Bacterial)	Middle East respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_5141	PF-4708671	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	NA	29652799
DrugRepV_5142	Pteridinone	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Increase (50 %)	NA	29652799
DrugRepV_5143	PF-4708671-BI-D1870	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	NA	29652799
DrugRepV_5144	SB203580	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	NA	29652799
DrugRepV_5145	PD0325901	NA	Melanoma | Solid Tumour | Solid Tumors | Advanced Cancer | Breast Neoplasms	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	Investigational	29652799
DrugRepV_5146	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	Approved, Investigational	29652799
DrugRepV_5147	Rapamycin-SB203580	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	NA	29652799
DrugRepV_5148	Rapamycin-PD0325901	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	NA	29652799
DrugRepV_5165	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Rift Valley fever virus	MP12-Luc	NA	Luciferase assay	Decrease (50 %)	Approved, Investigational	28442428
DrugRepV_5393	Zoniporide	NA	NA	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	NA	30700611
DrugRepV_5394	Zoniporide	NA	NA	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	NA	30700611
DrugRepV_5395	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5396	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5397	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5398	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5399	Apilimod	NA	Crohn's disease | Psoriasis | Psoriatic disorders	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	Investigational	30700611
DrugRepV_5400	Apilimod	NA	Crohn's disease | Psoriasis | Psoriatic disorders	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Investigational	30700611
DrugRepV_5401	Arbidol	NA	Viral infection	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	Investigational	30700611
DrugRepV_5402	Arbidol	NA	Viral infection	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Investigational	30700611
DrugRepV_5403	Clomiphene	Genito Urinary System and Sex Hormones	Female infertility	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5404	Clomiphene	Genito Urinary System and Sex Hormones	Female infertility	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5405	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5406	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved	30700611
DrugRepV_5407	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	Approved, Investigational	30700611
DrugRepV_5408	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Approved, Investigational	30700611
DrugRepV_6168	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	02--20		Luciferase assay	Decrease (50 %)	Approved	24858611
DrugRepV_6242	9-benzyl-6-[(1-methyl-4-nitro-4,5-dihydro-1H-imidazol-5-yl)methyl]-9H-purin-2-amine	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6243	2-{[(3-nitrophenyl)methyl]sulfanyl}-9H-purin-6-ol	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6244	2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)aniline	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6245	1-(4-Bromophenyl)-2-(ethylamino)-2-methylpropyl hydrodisulfide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6246	N-[4-(4-aminobenzenesulfonyl)phenyl]pyridine-3-carboxamide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6247	2-(2-{2-[(2E,5E)-3-ethyl-4-oxo-5-[(phenylamino)methylidene]-1,3-thiazolidin-2-ylidene]hydrazin-1-yl}-1,3-thiazol-5-yl)-N-(2-methylphenyl)acetamide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6248	(2E)-3-(3,4-dichlorophenyl)-1-[2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]prop-2-en-1-one	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6249	2-{[5-(4-{[(4-chlorophenyl)methylidene]amino}phenyl)-1,3,4-oxadiazol-2-yl]sulfanyl}-N-(2-nitrophenyl)acetamide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6250	1,3-bis({4-[(1E)-1-(carbamimidamidoimino)ethyl]phenyl})urea	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6957	FGI-106	NA	NA	Human immunodeficiency virus	NA		Luciferase assay	Decrease (50 %)	NA	19523489
DrugRepV_7210	CCG-6269	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (87 %)	NA	19651907
DrugRepV_7211	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (92 %)	NA	19651907
DrugRepV_7212	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (90 %)	NA	19651907
DrugRepV_7213	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (38 %)	NA	19651907
DrugRepV_7214	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (48 %)	NA	19651907
DrugRepV_7215	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (42 %)	NA	19651907
DrugRepV_7317	NITD008	Antiviral	NA	Japanese encephalitis virus	JEV?Pac?Rluc?Rep		Luciferase assay	Decrease (50 %)	NA	28779235
DrugRepV_7811	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Middle East respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	Approved, Investigational, Vet approved	32725286
DrugRepV_7812	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Middle East respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	Approved, Investigational, Vet approved	32725286